Relationship between Ideal Cardiovascular Health Metrics and Hearing Loss: A 10‐Year Retrospective Cohort Study

2021 ◽  
Author(s):  
Tzu‐Hsiang Tseng ◽  
Li‐Xian Yeo ◽  
Wei‐Liang Chen ◽  
Tung‐Wei Kao ◽  
Li‐Wei Wu ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Cardiovascular Health ◽  
Ideal Cardiovascular Health

Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study

The Lancet ◽  
2005 ◽  
Vol 366 (9499) ◽  
pp. 1797-1803 ◽  
Author(s):  
Joel G Ray ◽  
Marian J Vermeulen ◽  
Michael J Schull ◽  
Donald A Redelmeier
Keyword(s):  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Cardiovascular Health ◽  
Population Based

scholarly journals Combined Amplification and Sound Therapy for Individuals With Tinnitus and Coexisting Hearing Loss: A Retrospective Cohort Study

2021 ◽  
Vol 17 (6) ◽  
pp. 514-519
Author(s):  
Purushothaman Ganesan ◽  
◽  
Hansapani Rodrigo ◽  
Jason Schmiedge ◽  
Rob Reiter ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Sound Therapy

scholarly journals LO026: Outcomes of a provincial cardiac reperfusion strategy: a population-based, retrospective cohort study

CJEM ◽  
2016 ◽  
Vol 18 (S1) ◽  
pp. S38-S39
Author(s):  
J. Cook ◽  
A. Carter ◽  
A. Travers ◽  
R. Brown ◽  
E. Cain ◽  
...  
Keyword(s):  
Cohort Study ◽  
Nova Scotia ◽  
Retrospective Cohort Study ◽  
Rural Areas ◽  
Retrospective Cohort ◽  
Primary Outcome ◽  
Cardiovascular Health ◽  
Coronary Intervention ◽  
Reperfusion Strategy ◽  
The Impact

Introduction: Nova Scotia has a province wide reperfusion strategy for the treatment of patients presenting with acute ST-Elevation Myocardial Infarction (STEMI). Patients are referred for primary percutaneous coronary intervention (PPCI) if a first medical contact to device time can be achieved within 90 to 120 minutes; otherwise, fibrinolytic therapy is administered, as per guideline recommendations. Since 2011, Nova Scotian paramedics have been providing prehospital fibrinolysis (PHF) and prehospital catheterization (cath) lab activation for STEMI patients outside and within the PPCI catchment area, respectively. Patients who received fibrinolysis are transferred to a PCI facility if rescue PCI is required or if there are other indications for urgent intervention. This province wide approach is unique and the objective of this retrospective cohort study is to compare the impact of this approach on the primary outcome of 30-day mortality. Methods: For the study period, July 2011 to July 2013, STEMI patients who were diagnosed prehospital or in the ED who subsequently underwent reperfusion therapy were identified in the Emergency Health Services (EHS), Cardiovascular Information Systems (CVIS) and Cardiovascular Health Nova Scotia (CVHNS) databases. Baseline demographics and outcomes were then compared according to the treatment received: 1) PHF; 2) ED Fibrinolysis (EDF); 3) prehospital activated PPCI (EHS PPCI); and 4) ED activated PPCI (ED PPCI). Results: There were a total of 1107 STEMI patients identified during the study period, of whom 742 received lytic therapy (146 PHF; 596 EDF) and 332 underwent PPCI (202 EHS PPCI; 130 ED PPCI). Demographic variables were similar across the groups. The primary outcome of 30-day mortality was not significantly different across groups: 5 (3%) in PHF, 26 (4%) in EDF, 8 (4%) in EHS to PPCI and 2 (2%) in ED to PPCI. The number of rescue PCIs was 28 (19%) in PHF and 102 (17%) in EDF. Other outcomes (key timestamps) are pending. Conclusion: Our results show that the 30-day mortality was lowest for patients undergoing PPCI and slightly less for patients receiving pre-hospital fibrinolytic compared to those receiving ED fibrinolytic with no difference in the proportion requiring subsequent rescue PCI. The majority of patients in rural areas received EDF as opposed to PHF; pending results will show if this represents a delay in patient presentation after symptom onset.

scholarly journals Gout and hearing impairment in the elderly: a retrospective cohort study using the US Medicare claims data

BMJ Open ◽  
2018 ◽  
Vol 8 (8) ◽  
pp. e022854
Author(s):  
Jasvinder A Singh ◽  
John D Cleveland
Keyword(s):  
Older Adults ◽  
Hearing Loss ◽  
Cohort Study ◽  
Hearing Impairment ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Cox Regression ◽  
Incidence Rates ◽  
Sensitivity Analyses ◽  
Medicare Claims

ObjectivesTo evaluate whether gout is associated with a higher risk of hearing loss in older adults.DesignRetrospective cohort study.SettingUSA.Participants5% random sample of US Medicare claims 2006–2012, representative of US adults aged 65 years or older.Primary and secondary outcomesIncident (new) hearing loss identified by the presence of at least two claims at least 4 weeks apart with an International Classification of Diseases, Ninth Revision, 389.xx, with no respective claim in the baseline 1-year observation period.ResultsAmong the 1.71 million eligible people, 89 409 developed incident hearing impairment. The crude incidence rates of incident hearing impairment in people with versus without gout were 16.9 vs. 8.7 per 1000 person-years. Using Cox regression analyses adjusted for demographics, medical comorbidity and common cardiovascular and gout medications, we found that gout was associated with a significantly higher HR of incident hearing impairment, HR was 1.44 (95% CI 1.40 to 1.49, p<0.0001). Findings were confirmed in sensitivity analyses that substituted continuous Charlson-Romano Index with categorical variable or all comorbidities and additionally cardiovascular risk factors, with minimal attenuation of HR.ConclusionsGout is associated with a higher risk of development of hearing loss in older adults. Future studies need to assess the underlying mechanisms of this association.

Sign in / Sign up

Export Citation Format

Share Document